“a favorable trend”

However, pooled analyses regarding disability progression showed only a favorable trend but did not reach statistical significance [ 61 ].

However, the observation of the retina after the first injection, when edema was reduced, and the actual retinal vascularisation was revealed, showed a favorable trend toward increasing vessel density at subsequent measurement timepoints until the end of this study.

Female sex showed a favorable trend toward improved survival, while patients with a family history of tumors tended to have lower risk in the fully adjusted model.

While escalation accuracy showed only a favorable trend after correction, overall results support ESS as low-cost, scalable interventions to strengthen laboratory safety performance.

TT shows a favorable trend in myocardial ischemia outcomes.

Despite observing a favorable trend, such as a 21% reduction in risk, statistical significance was not attained 34 .

60.0 %) and showed a favorable trend in persistent AF. 40 Although procedure durations and energy delivery times increased, no procedure-related deaths were reported.

37 – 41 Also, the proportion of subjects treated for arterial hypertension, dyslipidemia, or diabetes increased with age, but the chance of being controlled did not display a favorable trend.

The results of the pilot study provided information on the feasibility of using virtual reality equipment in this group of patients and showed a favorable trend of changes in the working memory in individual patients.

A favorable trend toward improved OS was seen in the SG plus pembrolizumab group, with an HR of 0.89 (95% CI, 0.62–1.29), although statistical significance was not reached [ 54 ].

A favorable trend was also noted in UIE and RVEF, although these outcomes did not reach statistical significance.

However, our study stands out from those previously published by demonstrating that, in subgroup analyses, despite a favorable trend towards the use of LCI, no statistically significant differences were observed compared with WLI.

When limited to the patients with myxoid round cell liposarcoma, the response rate was elevated to 21% (3/14), and the progression-free survival was 7.3 months, showing a favorable trend.

Although the present study did not show statistically significant improvements with the addition of WBV to intensive therapy, the intervention was safe, well tolerated, and demonstrated a favorable trend.

In our cohort, objective postoperative BCVA at 3 months was better after EEA, and visual field indices showed a favorable trend.

Median OS displayed a favorable trend for the combination arm, with a survival rate of 24.4 months in the chemotherapy group and no median reached in the amivantamab group.

A favorable trend has been observed with NRL allergy, considered to be the most common form of CUS among health workers [ 13 ].

Previous studies have indicated a favorable trend in the adoption of technology for self-management and prevention of complications, thereby underscoring the significant role that mobile applications and analogous tools play in empowering patients to assume responsibility for their diabetic foot ulcer care.

The addition of durvalumab without olaparib (DBC) showed a favorable trend toward improved survival, albeit without statistical significance [ 9 ].

In their single institution retrospective study, they showed a favorable trend for neoadjuvant chemotherapy (versus a surgery-first approach) among patients of 75 years old and over.

Although no statistically significant differences were observed in 28-day and 90-day mortality rates, a favorable trend toward clinical safety and effectiveness was observed with the restrictive approach, consistent with existing literature.

Regarding prognostic impact, our data show a favorable trend in overall survival for patients who received targeted therapies guided by ctDNA results.

It has been shown that there is a favorable trend in overall survival with platinum-based therapies in patients with HRR.

Findings showed a favorable trend for more rapid effects than in patients with HAE-1/2, including a shorter median time to complete resolution and shorter median total attack duration, though the only statistically significant difference between the two patient groups in this cohort was mean time from first icatibant administration to complete resolution of symptoms.

The trial adopted a transperitoneal approach but was prematurely terminated for futility owing to the absence of a favorable trend in surgical or functional outcomes.